An interventional study of Lung Ultrasound in Acute Decompensated Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.
Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2026, is one of 24 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 68th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 3 · Phase 4 1
First in 1997; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 36 across the 48 interventional studies, 63 across the 18 observational. Of the 48 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
9 of the studies in Heart Failure by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06874556Mayo ClinicA Study of Paramedic HF Management | 2026-12 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
| NCT06660732Mayo ClinicRilonacept in Subjects With Cardiac Sarcoidosis | 2027-03 |
| NCT05592847Mayo ClinicA Study of the Effect of a Nurse Navigator Program on High Risk Patients | 2027-04 |
| NCT07083011Mayo ClinicA Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 69 studies in Heart Failure by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine shorter hospitalization length as well as a reduced rates of recurrent heart failure hospitalization compared to current standard of care in Acute Decompensated Heart Failure. A 1-day reduction in hospital length of stay in unblinded subjects receiving daily HF-FOCUS examinations compared to a blinded standard of care arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Admission diagnosis of either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing daily lung ultrasound with the results reported to the provider care teams on admission and each morning
Diagnostic Test: Lung Ultrasound
Patients undergoing daily lung ultrasound but the results will be blinded to the provider care teams
Diagnostic Test: Lung Ultrasound
Patients will undergo lung ultrasound assessments at hospital admission, daily throughout admission, and at hospital discharge.
Number of days in the hospital
The number of days a patient is in the hospital will be determined by the day of admission and day of discharge. The day of discharge will be defined as when the consultant physician states that the patient is medically ready for discharge from the hospital.
Time frame: Baseline
Number of re-hospitalized patients
Number of patients re-hospitalized will be determined by the number of patients admitted to the hospital post discharge
Time frame: Baseline
Number of deaths
Number of deaths will be determined by number of patient deaths due to any cause
Time frame: Baseline
Change in effective diuresis
Diuresis will be measured from a urine sample and calculated by total diuresis in liters/admission weight in kilograms
Time frame: Baseline, up to 90 Days
Change in diuretic dosing
Diuretic dosing will be measured in mg
Time frame: Baseline, up to 90 Days
Change in Lung Congestion
Lung congestion will be measured using a lung ultrasound and measured as a percentage
Time frame: Baseline, up to 90 Days
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 22 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.